BPL-1318: Study of Degenerescence CSF Hallmarks in Older Bipolar Patients

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Unknown status
CT.gov ID
NCT02836054
Collaborator
(none)
30
1
2
73
0.4

Study Details

Study Description

Brief Summary

Analysis of 4 CSF Alzheimer's disease biomarkers (total and phosphorylated tau protein, Aß40 and Aß1-42) and morphological brain MRI in older patients (>60 year's old) with bipolar disorder, after an evaluation of their cognitive functions.

Comparison between two groups of patients : patients with cognitive disorders and patients without cognitive disorders.

The objective is to describe and compare the profile of those biomarkers in those two populations.

Condition or Disease Intervention/Treatment Phase
  • Procedure: lumbar puncture (LP)
  • Procedure: brain MRI
N/A

Detailed Description

Describe the profile of the 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in the cerebrospinal fluid (Total Tau proteins, phosphorylated, Aß40 and Aß1-42) for old subjects suffering from bipolar disorder with or without cognitive impairment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Study of Degenerescence CSF Hallmarks in Older Bipolar Patients
Study Start Date :
Nov 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: Patients with cognitive disorders

lumbar punction + brain MRI

Procedure: lumbar puncture (LP)

Procedure: brain MRI

Other: Patients without cognitive disorders

lumbar punction + brain MRI

Procedure: lumbar puncture (LP)

Procedure: brain MRI

Outcome Measures

Primary Outcome Measures

  1. Profile 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in cerebrospinal fluid of aged subjects with bipolar disorder : Total Tau proteins, phosphorylated Tau proteins, Aß40 and Aß1-42 concentration [3 hours 50 minutes (total of the 4 primary outcome measures described)]

    The mean concentration of each biomarker is measured independently. The analysis between the 2 groups is done with the profile of the 4 biomarkers, not only between the profile of one biomarker to another.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • male or female between 60 and 80

  • french-speaking, reading and writing patient

  • affiliation to the French Social Security

  • written informed consent obtained from the patient

  • agree to undergo a lumbar puncture

  • easy accessibility for the lumbar puncture

  • Mini Mental State Examination (MMSE) > 20

  • bipolar patients :

  • type I or II

  • state of euthymia for at least 4 weeks

  • stable psychotropic drug treatment for at least 8 weeks

  • no electroconvulsive therapy during the 6 months before inclusion

  • distribution in the "with cognitive disorder" or "without cognitive disorder" group is function of the result of the neuropsychological evaluation

Non-inclusion Criteria :
  • severe visual or auditory disorder

  • advanced lumbar osteoarthritis

  • history of severe head injury, neurological disorders, diagnosed dementia

  • addiction weaned for less than 12 months

  • forced hospitalization in psychiatry

  • MRI contraindications

  • LP contraindications

Exclusion Criteria:
  • at least one of the outcome measures can't be performed :

  • MRI

  • LP : anticoagulation, bad accessibility

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital, Grenoble Grenoble Isère France 38043

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

  • Principal Investigator: Lora COHEN, CMRR, Pavillon de Neurologie, C.H.U. de Grenoble

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT02836054
Other Study ID Numbers:
  • 38RC13.408
  • 2013-A00930-45
First Posted:
Jul 18, 2016
Last Update Posted:
Jan 7, 2019
Last Verified:
Jan 1, 2019
Keywords provided by University Hospital, Grenoble
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 7, 2019